Abstract 1802
Background
Targeting programmed cell death-1 receptor (PD-1) or its ligand PD-L1 has failed to provide durable clinical benefit for a majority of patients with solid carcinomas. Recent preclinical and clinical data suggests that addition of the IL-15 superagonist N-803 improves response rates to anti-PD-1 or anti-PD-L1 therapy. Thus, we hypothesized that N-809, a novel bifunctional agent comprised of N-803 fused to two single chain anti-PD-L1 variable region domains, would promote potent anti-tumor efficacy and immune activation in murine models of solid carcinomas.
Methods
The functionality of the N-809 components was examined in vitro. Anti-tumor efficacy of N-809 versus a clinically relevant dose of N-803 + anti-PD-L1 was assessed using murine MC38 colon and 4T1 triple negative breast tumor models. The immune-mediated mechanism of N-809 was examined in spleen and tumor using comprehensive flow-based analyses and functional assays. Serum cytokine levels were also measured. Finally, effects on tumor gene expression were examined using Nanostring. Nant biosciences provided N-809 as per Cooperative Research and Development Agreement with NCI.
Results
In vitrostudies confirmed that both components of N-809 were functional. N-809 drastically reduced MC38 tumor burden leading to increased survival and significantly reduced spontaneous lung metastasis of 4T1 tumors. In both tumor models, N-809 had improved efficacy versus a clinically relevant dose of N-803 + anti-PD-L1. In the MC38 model, N-809 increased serum levels of IFNg, TNFa, and IL-10. Depletion studies revealed that CD8+T and NK cells are required for the anti-tumor efficacy of N-809. The immune analysis showed enhanced CD8+ T and NK cell tumor infiltration, activation, and function. To determine the mechanism of the increased CD8 and NK cell infiltration, analyses were performed to examine tumor chemokines and inhibition of immune cell migration. Gene analysis revealed changes in chemokines, chemokine receptors, and immune response genes.
Conclusions
N-809 has anti-tumor efficacy in two murine carcinoma model mediated by increasing the number, activation, and function of CD8+ T cells and NK cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Funding
Nant Bioscience.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract